

Supplementary Table 1a Suspected constitutional pathogenic variants according to tumor type and gene involved with an indication to genetic testing - Ovary

	Variants with indication to genetic counseling	Variants with no clinical indication to perform germline test	Variants tested in leukocyte DNA		
			All variants	Confirmed	Not confirmed
	n=265	n=15	n=233	n=172	n=61
Gene					
<i>ATM</i>	8	1	7	5	2
<i>BAP1</i>	0	0	0	0	0
<i>BARD1</i>	2	0	1	1	0
<i>BRCA1</i>	114	0	111	81	30
<i>BRCA2</i>	61	0	58	44	14
<i>BRIP1</i>	6	0	5	4	1
<i>CHEK2</i>	3	0	3	2	1
<i>DICER1</i>	3	2	1	0	1
<i>FH</i>	0	0	0	0	0
<i>FLCN</i>	0	0	0	0	0
<i>MLH1</i>	6	0	6	4	2
<i>MSH2</i>	4	0	4	1	3
<i>MSH6</i>	9	0	7	4	3
<i>MUTYH</i>	2	0	2	2	0
<i>NF1</i>	9	8	0	0	0
<i>PALB2</i>	7	0	6	6	0
<i>PMS2</i>	1	0	1	1	0
<i>POLD1</i>	1	0	0	0	0
<i>POLE</i>	3	1	2	1	1
<i>PTCH1</i>	3	2	0	0	0
<i>PTEN</i>	1	0	1	0	1
<i>RAD51C</i>	11	0	9	8	1
<i>RAD51D</i>	4	0	4	4	0
<i>RET</i>	2	1	1	1	0
<i>SDHA</i>	2	0	2	2	0
<i>SDHB</i>	2	0	2	1	1
<i>SDHC</i>	0	0	0	0	0
<i>SMAD3</i>	0	0	0	0	0
<i>SMARCB1</i>	1	0	0	0	0
<i>TSC2</i>	0	0	0	0	0

Results are presented as n (%) except where indicated.

Supplementary Table 1b Suspected constitutional pathogenic variants according to tumor type and gene involved with an indication to genetic testing - Endometrium

	Variants with indication to genetic counseling	Variants with no clinical indication to perform germline test	Variants tested in leukocyte DNA		
			All variants	Confirmed	Not confirmed
	n=147	n=8	n=99	n=48	n=51
Gene					
<i>ATM</i>	27	1	12	4	8
<i>BAP1</i>	0	0	0	0	0
<i>BARD1</i>	3	1	1	0	1
<i>BRCA1</i>	6	0	5	3	2
<i>BRCA2</i>	16	0	9	4	5
<i>BRIP1</i>	3	0	3	1	2
<i>CHEK2</i>	9	0	5	1	4
<i>DICER1</i>	6	2	3	0	3
<i>FH</i>	0	0	0	0	0
<i>FLCN</i>	0	0	0	0	0
<i>MLH1</i>	9	0	9	3	6
<i>MSH2</i>	25	0	23	13	10
<i>MSH6</i>	19	0	14	11	3
<i>MUTYH</i>	4	0	4	4	0
<i>NF1</i>	1	1	0	0	0
<i>PALB2</i>	2	0	1	1	0
<i>PMS2</i>	1	0	1	1	0
<i>POLD1</i>	1	0	0	0	0
<i>POLE</i>	2	0	2	0	2
<i>PTCH1</i>	9	3	4	0	4
<i>PTEN</i>	1	0	1	0	1
<i>RAD51C</i>	0	0	0	0	0
<i>RAD51D</i>	1	0	1	1	0
<i>RET</i>	0	0	0	0	0
<i>SDHA</i>	1	0	1	1	0
<i>SDHB</i>	0	0	0	0	0
<i>SDHC</i>	1	0	0	0	0
<i>SMAD3</i>	0	0	0	0	0
<i>SMARCB1</i>	0	0	0	0	0
<i>TSC2</i>	0	0	0	0	0

Results are presented as n (%) except where indicated.

Supplementary Table 1c Suspected constitutional pathogenic variants according to tumor type and gene involved with an indication to genetic testing - Lung

	Variants with indication to genetic counseling	Variants with no clinical indication to perform germline test	Variants tested in leukocyte DNA		
			All variants	Confirmed	Not confirmed
	n=45	n=5	n=14	n=6	n=8
Gene					
<i>ATM</i>	11	0	4	3	1
<i>BAP1</i>	1	0	0	0	0
<i>BARD1</i>	1	0	0	0	0
<i>BRCA1</i>	5	0	3	2	1
<i>BRCA2</i>	6	0	3	1	2
<i>BRIP1</i>	0	0	0	0	0
<i>CHEK2</i>	2	1	1	0	1
<i>DICER1</i>	0	0	0	0	0
<i>FH</i>	0	0	0	0	0
<i>FLCN</i>	0	0	0	0	0
<i>MLH1</i>	1	0	1	0	1
<i>MSH2</i>	0	0	0	0	0
<i>MSH6</i>	2	0	1	0	1
<i>MUTYH</i>	0	0	0	0	0
<i>NF1</i>	6	3	0	0	0
<i>PALB2</i>	3	0	0	0	0
<i>PMS2</i>	0	0	0	0	0
<i>POLD1</i>	1	0	0	0	0
<i>POLE</i>	0	0	0	0	0
<i>PTCH1</i>	0	0	0	0	0
<i>PTEN</i>	0	0	0	0	0
<i>RAD51C</i>	2	0	0	0	0
<i>RAD51D</i>	1	0	1	0	1
<i>RET</i>	0	0	0	0	0
<i>SDHA</i>	0	0	0	0	0
<i>SDHB</i>	1	0	0	0	0
<i>SDHC</i>	0	0	0	0	0
<i>SMAD3</i>	1	0	0	0	0
<i>SMARCB1</i>	0	0	0	0	0
<i>TSC2</i>	1	1	0	0	0

Results are presented as n (%) except where indicated.

Supplementary Table 1d Suspected constitutional pathogenic variants according to tumor type and gene involved with an indication to genetic testing - Colorectum

	Variants with indication to genetic counseling	Variants with no clinical indication to perform germline test	Variants tested in leukocyte DNA		
			All variants	Confirmed	Not confirmed
	n=26	n=4	n=10	n=5	n=5
Gene					
<i>ATM</i>	4	0	1	0	1
<i>BAP1</i>	0	0	0	0	0
<i>BARD1</i>	2	1	0	0	0
<i>BRCA1</i>	0	0	0	0	0
<i>BRCA2</i>	4	1	2	1	1
<i>BRIP1</i>	3	0	0	0	0
<i>CHEK2</i>	3	1	1	0	1
<i>DICER1</i>	0	0	0	0	0
<i>FH</i>	0	0	0	0	0
<i>FLCN</i>	1	0	1	0	1
<i>MLH1</i>	5	0	5	4	1
<i>MSH2</i>	0	0	0	0	0
<i>MSH6</i>	0	0	0	0	0
<i>MUTYH</i>	0	0	0	0	0
<i>NF1</i>	0	0	0	0	0
<i>PALB2</i>	0	0	0	0	0
<i>PMS2</i>	0	0	0	0	0
<i>POLD1</i>	0	0	0	0	0
<i>POLE</i>	0	0	0	0	0
<i>PTCH1</i>	1	1	0	0	0
<i>PTEN</i>	0	0	0	0	0
<i>RAD51C</i>	0	0	0	0	0
<i>RAD51D</i>	0	0	0	0	0
<i>RET</i>	0	0	0	0	0
<i>SDHA</i>	0	0	0	0	0
<i>SDHB</i>	0	0	0	0	0
<i>SDHC</i>	0	0	0	0	0
<i>SMAD3</i>	3	0	0	0	0
<i>SMARCB1</i>	0	0	0	0	0
<i>TSC2</i>	0	0	0	0	0

Results are presented as n (%) except where indicated.

Supplementary Table 1e Suspected constitutional pathogenic variants according to tumor type and gene involved with an indication to genetic testing - Pancreas

	Variants with indication to genetic counseling	Variants with no clinical indication to perform germline test	Variants tested in leukocyte DNA		
			All variants	Confirmed	Not confirmed
Gene	n=14	n=0	n=10	n=9	n=1
<i>ATM</i>	5	0	3	3	0
<i>BAP1</i>	0	0	0	0	0
<i>BARD1</i>	1	0	1	1	0
<i>BRCA1</i>	1	0	1	1	0
<i>BRCA2</i>	4	0	2	2	0
<i>BRIP1</i>	0	0	0	0	0
<i>CHEK2</i>	0	0	0	0	0
<i>DICER1</i>	0	0	0	0	0
<i>FH</i>	1	0	1	1	0
<i>FLCN</i>	0	0	0	0	0
<i>MLH1</i>	0	0	0	0	0
<i>MSH2</i>	0	0	0	0	0
<i>MSH6</i>	1	0	1	0	1
<i>MUTYH</i>	0	0	0	0	0
<i>NF1</i>	0	0	0	0	0
<i>PALB2</i>	1	0	1	1	0
<i>PMS2</i>	0	0	0	0	0
<i>POLD1</i>	0	0	0	0	0
<i>POLE</i>	0	0	0	0	0
<i>PTCH1</i>	0	0	0	0	0
<i>PTEN</i>	0	0	0	0	0
<i>RAD51C</i>	0	0	0	0	0
<i>RAD51D</i>	0	0	0	0	0
<i>RET</i>	0	0	0	0	0
<i>SDHA</i>	0	0	0	0	0
<i>SDHB</i>	0	0	0	0	0
<i>SDHC</i>	0	0	0	0	0
<i>SMAD3</i>	0	0	0	0	0
<i>SMARCB1</i>	0	0	0	0	0
<i>TSC2</i>	0	0	0	0	0

Results are presented as n (%) except where indicated.

Supplementary Table 1f Suspected constitutional pathogenic variants according to tumor type and gene involved with an indication to genetic testing - Cholangiocarcinoma

	Variants with indication to genetic counseling	Variants with no clinical indication to perform germline test	Variants tested in leukocyte DNA		
			All variants	Confirmed	Not confirmed
Gene	n=7	n=0	n=3	n=1	n=2
<i>ATM</i>	1	0	0	0	0
<i>BAP1</i>	3	0	2	0	2
<i>BARD1</i>	0	0	0	0	0
<i>BRCA1</i>	1	0	1	1	0
<i>BRCA2</i>	1	0	0	0	0
<i>BRIP1</i>	0	0	0	0	0
<i>CHEK2</i>	0	0	0	0	0
<i>DICER1</i>	1	0	0	0	0
<i>FH</i>	0	0	0	0	0
<i>FLCN</i>	0	0	0	0	0
<i>MLH1</i>	0	0	0	0	0
<i>MSH2</i>	0	0	0	0	0
<i>MSH6</i>	0	0	0	0	0
<i>MUTYH</i>	0	0	0	0	0
<i>NF1</i>	0	0	0	0	0
<i>PALB2</i>	0	0	0	0	0
<i>PMS2</i>	0	0	0	0	0
<i>POLD1</i>	0	0	0	0	0
<i>POLE</i>	0	0	0	0	0
<i>PTCH1</i>	0	0	0	0	0
<i>PTEN</i>	0	0	0	0	0
<i>RAD51C</i>	0	0	0	0	0
<i>RAD51D</i>	0	0	0	0	0
<i>RET</i>	0	0	0	0	0
<i>SDHA</i>	0	0	0	0	0
<i>SDHB</i>	0	0	0	0	0
<i>SDHC</i>	0	0	0	0	0
<i>SMAD3</i>	0	0	0	0	0
<i>SMARCB1</i>	0	0	0	0	0
<i>TSC2</i>	0	0	0	0	0

Results are presented as n (%) except where indicated.

Supplementary Table 1g Suspected constitutional pathogenic variants according to tumor type and gene involved with an indication to genetic testing - Melanoma

	Variants with indication to genetic counseling	Variants with no clinical indication to perform germline test	Variants tested in leukocyte DNA		
			All variants	Confirmed	Not confirmed
	n=7	n=0	n=2	n=1	n=1
Gene					
<i>ATM</i>	2	0	0	0	0
<i>BAP1</i>	0	0	0	0	0
<i>BARD1</i>	0	0	0	0	0
<i>BRCA1</i>	1	0	1	1	0
<i>BRCA2</i>	1	0	1	0	1
<i>BRIP1</i>	0	0	0	0	0
<i>CHEK2</i>	0	0	0	0	0
<i>DICER1</i>	0	0	0	0	0
<i>FH</i>	0	0	0	0	0
<i>FLCN</i>	0	0	0	0	0
<i>MLH1</i>	0	0	0	0	0
<i>MSH2</i>	0	0	0	0	0
<i>MSH6</i>	0	0	0	0	0
<i>MUTYH</i>	0	0	0	0	0
<i>NF1</i>	2	0	0	0	0
<i>PALB2</i>	0	0	0	0	0
<i>PMS2</i>	0	0	0	0	0
<i>POLD1</i>	0	0	0	0	0
<i>POLE</i>	0	0	0	0	0
<i>PTCH1</i>	0	0	0	0	0
<i>PTEN</i>	0	0	0	0	0
<i>RAD51C</i>	0	0	0	0	0
<i>RAD51D</i>	0	0	0	0	0
<i>RET</i>	0	0	0	0	0
<i>SDHA</i>	0	0	0	0	0
<i>SDHB</i>	0	0	0	0	0
<i>SDHC</i>	0	0	0	0	0
<i>SMAD3</i>	0	0	0	0	0
<i>SMARCB1</i>	1	0	0	0	0
<i>TSC2</i>	0	0	0	0	0

Results are presented as n (%) except where indicated.

Supplementary Table 1h Suspected constitutional pathogenic variants according to tumor type and gene involved with an indication to genetic testing - Prostate

	Variants with indication to genetic counseling	Variants with no clinical indication to perform germline test	Variants tested in leukocyte DNA		
			All variants	Confirmed	Not confirmed
	n=8	n=0	n=4	n=3	n=1
Gene					
<i>ATM</i>	3	0	1	1	0
<i>BAP1</i>	0	0	0	0	0
<i>BARD1</i>	0	0	0	0	0
<i>BRCA1</i>	0	0	0	0	0
<i>BRCA2</i>	3	0	1	0	1
<i>BRIP1</i>	0	0	0	0	0
<i>CHEK2</i>	1	0	1	1	0
<i>DICER1</i>	0	0	0	0	0
<i>FH</i>	0	0	0	0	0
<i>FLCN</i>	0	0	0	0	0
<i>MLH1</i>	0	0	0	0	0
<i>MSH2</i>	0	0	0	0	0
<i>MSH6</i>	0	0	0	0	0
<i>MUTYH</i>	0	0	0	0	0
<i>NF1</i>	0	0	0	0	0
<i>PALB2</i>	0	0	0	0	0
<i>PMS2</i>	0	0	0	0	0
<i>POLD1</i>	0	0	0	0	0
<i>POLE</i>	0	0	0	0	0
<i>PTCH1</i>	0	0	0	0	0
<i>PTEN</i>	0	0	0	0	0
<i>RAD51C</i>	1	0	1	1	0
<i>RAD51D</i>	0	0	0	0	0
<i>RET</i>	0	0	0	0	0
<i>SDHA</i>	0	0	0	0	0
<i>SDHB</i>	0	0	0	0	0
<i>SDHC</i>	0	0	0	0	0
<i>SMAD3</i>	0	0	0	0	0
<i>SMARCB1</i>	0	0	0	0	0
<i>TSC2</i>	0	0	0	0	0

Results are presented as n (%) except where indicated.

Supplementary Table 1h Suspected constitutional pathogenic variants according to tumor type and gene involved with an indication to genetic testing - Melanoma

	Variants with indication to genetic counseling	Variants with no clinical indication to perform germline test	Variants tested in leukocyte DNA		
			All variants	Confirmed	Not confirmed
	n=7	n=0	n=2	n=1	n=1
Gene					
<i>ATM</i>	2	0	0	0	0
<i>BAP1</i>	0	0	0	0	0
<i>BARD1</i>	0	0	0	0	0
<i>BRCA1</i>	1	0	1	1	0
<i>BRCA2</i>	1	0	1	0	1
<i>BRIP1</i>	0	0	0	0	0
<i>CHEK2</i>	0	0	0	0	0
<i>DICER1</i>	0	0	0	0	0
<i>FH</i>	0	0	0	0	0
<i>FLCN</i>	0	0	0	0	0
<i>MLH1</i>	0	0	0	0	0
<i>MSH2</i>	0	0	0	0	0
<i>MSH6</i>	0	0	0	0	0
<i>MUTYH</i>	0	0	0	0	0
<i>NF1</i>	2	0	0	0	0
<i>PALB2</i>	0	0	0	0	0
<i>PMS2</i>	0	0	0	0	0
<i>POLD1</i>	0	0	0	0	0
<i>POLE</i>	0	0	0	0	0
<i>PTCH1</i>	0	0	0	0	0
<i>PTEN</i>	0	0	0	0	0
<i>RAD51C</i>	0	0	0	0	0
<i>RAD51D</i>	0	0	0	0	0
<i>RET</i>	0	0	0	0	0
<i>SDHA</i>	0	0	0	0	0
<i>SDHB</i>	0	0	0	0	0
<i>SDHC</i>	0	0	0	0	0
<i>SMAD3</i>	0	0	0	0	0
<i>SMARCB1</i>	1	0	0	0	0
<i>TSC2</i>	0	0	0	0	0

Results are presented as n (%) except where indicated.

Supplementary Table 1i Suspected constitutional pathogenic variants according to tumor type and gene involved with an indication to genetic testing - Thyroid

	Variants with indication to genetic counseling	Variants with no clinical indication to perform germline test	Variants tested in leukocyte DNA		
			All variants	Confirmed	Not confirmed
Gene	n=4	n=0	n=3	n=2	n=1
<i>ATM</i>	0	0	0	0	0
<i>BAP1</i>	0	0	0	0	0
<i>BARD1</i>	0	0	0	0	0
<i>BRCA1</i>	0	0	0	0	0
<i>BRCA2</i>	0	0	0	0	0
<i>BRIP1</i>	0	0	0	0	0
<i>CHEK2</i>	0	0	0	0	0
<i>DICER1</i>	0	0	0	0	0
<i>FH</i>	0	0	0	0	0
<i>FLCN</i>	0	0	0	0	0
<i>MLH1</i>	0	0	0	0	0
<i>MSH2</i>	0	0	0	0	0
<i>MSH6</i>	0	0	0	0	0
<i>MUTYH</i>	0	0	0	0	0
<i>NF1</i>	1	0	0	0	0
<i>PALB2</i>	0	0	0	0	0
<i>PMS2</i>	0	0	0	0	0
<i>POLD1</i>	0	0	0	0	0
<i>POLE</i>	0	0	0	0	0
<i>PTCH1</i>	0	0	0	0	0
<i>PTEN</i>	0	0	0	0	0
<i>RAD51C</i>	0	0	0	0	0
<i>RAD51D</i>	0	0	0	0	0
<i>RET</i>	3	0	3	2	1
<i>SDHA</i>	0	0	0	0	0
<i>SDHB</i>	0	0	0	0	0
<i>SDHC</i>	0	0	0	0	0
<i>SMAD3</i>	0	0	0	0	0
<i>SMARCB1</i>	0	0	0	0	0
<i>TSC2</i>	0	0	0	0	0

Results are presented as n (%) except where indicated.

Supplementary Table 1j Suspected constitutional pathogenic variants according to tumor type and gene involved with an indication to genetic testing - GIST

	Variants with indication to genetic counseling	Variants with no clinical indication to perform germline test	Variants tested in leukocyte DNA		
			All variants	Confirmed	Not confirmed
Gene	n=2	n=0	n=2	n=2	n=0
<i>ATM</i>	0	0	0	0	0
<i>BAP1</i>	0	0	0	0	0
<i>BARD1</i>	0	0	0	0	0
<i>BRCA1</i>	0	0	0	0	0
<i>BRCA2</i>	0	0	0	0	0
<i>BRIP1</i>	0	0	0	0	0
<i>CHEK2</i>	0	0	0	0	0
<i>DICER1</i>	0	0	0	0	0
<i>FH</i>	0	0	0	0	0
<i>FLCN</i>	0	0	0	0	0
<i>MLH1</i>	0	0	0	0	0
<i>MSH2</i>	0	0	0	0	0
<i>MSH6</i>	0	0	0	0	0
<i>MUTYH</i>	0	0	0	0	0
<i>NF1</i>	1	0	1	1	0
<i>PALB2</i>	0	0	0	0	0
<i>PMS2</i>	0	0	0	0	0
<i>POLD1</i>	0	0	0	0	0
<i>POLE</i>	0	0	0	0	0
<i>PTCH1</i>	0	0	0	0	0
<i>PTEN</i>	0	0	0	0	0
<i>RAD51C</i>	0	0	0	0	0
<i>RAD51D</i>	0	0	0	0	0
<i>RET</i>	0	0	0	0	0
<i>SDHA</i>	0	0	0	0	0
<i>SDHB</i>	0	0	0	0	0
<i>SDHC</i>	1	0	1	1	0
<i>SMAD3</i>	0	0	0	0	0
<i>SMARCB1</i>	0	0	0	0	0
<i>TSC2</i>	0	0	0	0	0

Results are presented as n (%) except where indicated.

Supplementary Table 1k Suspected constitutional pathogenic variants according to tumor type and gene involved with an indication to genetic testing - Breast

	Variants with indication to genetic counseling	Variants with no clinical indication to perform germline test	Variants tested in leukocyte DNA		
			All variants	Confirmed	Not confirmed
Gene	n=2	n=1	n=0	n=0	n=0
<i>ATM</i>	0	0	0	0	0
<i>BAP1</i>	0	0	0	0	0
<i>BARD1</i>	0	0	0	0	0
<i>BRCA1</i>	0	0	0	0	0
<i>BRCA2</i>	0	0	0	0	0
<i>BRIP1</i>	0	0	0	0	0
<i>CHEK2</i>	0	0	0	0	0
<i>DICER1</i>	0	0	0	0	0
<i>FH</i>	0	0	0	0	0
<i>FLCN</i>	0	0	0	0	0
<i>MLH1</i>	0	0	0	0	0
<i>MSH2</i>	0	0	0	0	0
<i>MSH6</i>	0	0	0	0	0
<i>MUTYH</i>	0	0	0	0	0
<i>NF1</i>	1	1	0	0	0
<i>PALB2</i>	0	0	0	0	0
<i>PMS2</i>	0	0	0	0	0
<i>POLD1</i>	0	0	0	0	0
<i>POLE</i>	0	0	0	0	0
<i>PTCH1</i>	0	0	0	0	0
<i>PTEN</i>	0	0	0	0	0
<i>RAD51C</i>	1	0	0	0	0
<i>RAD51D</i>	0	0	0	0	0
<i>RET</i>	0	0	0	0	0
<i>SDHA</i>	0	0	0	0	0
<i>SDHB</i>	0	0	0	0	0
<i>SDHC</i>	0	0	0	0	0
<i>SMAD3</i>	0	0	0	0	0
<i>SMARCB1</i>	0	0	0	0	0
<i>TSC2</i>	0	0	0	0	0

Results are presented as n (%) except where indicated.

Supplementary Table 2 – Constitutional pathogenic variants detected by additional constitutional testing and/or not fulfilling ESMO criteria

Disease	ID patient	Additional variant #1	Additional variant #2
Primary malignant neoplasm of ovary	1	BRCA1: deletion of exons 18-19	
Primary malignant neoplasm of ovary	2	CHEK2: c.433C>T - p.Arg145Trp	
Endometrial carcinoma	3	MSH2: Exon 16 deletion	
Primary malignant neoplasm of pancreas	4	BRCA1: deletion of exons 1-2	
Endometrial carcinoma	5	MSH2: c.2231T>C - (p.Leu744Ser)	
Primary malignant adenocarcinoma of colon	6	MSH2: c.942+2T>A - p.?	
Primary malignant neoplasm of ovary	7	RAD51C: c.904+5G>T	
Endometrial carcinoma	8	MLH1: c.588+5G>T - p.?	
Endometrioid carcinoma of ovary	9	MSH6: c.3261dup - p.Phe1088fs	
Primary malignant neoplasm of ovary	10	BRCA1: deletion of exons 4-7	
Primary malignant neoplasm of ovary	11	RAD51C: c.904+5G>T	
Primary malignant neoplasm of ovary	12	RAD51C: c.904+5G>T	
Endometrioid carcinoma of ovary	13	MSH6: c.3261dup - p.Phe1088fs	
Endometrial carcinoma	14	MSH2: c.2647dup - p.Ile883fs	
Primary malignant neoplasm of ovary	15	BRCA1: deletion of exons 21-22	CDKN2A: c.301G>T - p.Gly101Trp
Primary malignant neoplasm of ovary	16	BRCA1: deletion of exons 1-2	
Primary malignant neoplasm of ovary	17	BRCA1: deletion of exons 17-18	